Physician profile
Julius Brandon Elmore
NPI 1457523367
$54,917.52
in general payments reported to CMS, 2019-2025
35 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,704 · 2020: $6,739 · 2021: $7,672 · 2022: $2,519 · 2023: $2,762 · 2024: $2,804 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $8,016 · Travel and Lodging: $4,199 · Education: $37.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,031.25 |
| Food and Beverage | $8,016.17 |
| Travel and Lodging | $4,199.49 |
| Education | $37.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21,048.79 | 2019-2025 | Watchman, Watchman Access System, Watchman Flx |
| Medtronic Vascular, INC. | $11,446.47 | 2019-2020 | |
| Medtronic, INC. | $8,329.13 | 2021-2025 | Corevalve Evolut R, Onyx Frontier |
| Philips North America LLC | $4,159.29 | 2023-2025 | Igt Devices Undivided, (Bq9) Coronary Ivus, (Br4) Coronary Undivided |
| Edwards Lifesciences Corporation | $2,955.02 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Angiodynamics, INC. | $1,823.66 | 2019-2024 | Alphavac |
| Abbott Laboratories | $1,111.32 | 2020-2025 | Portico, Aptivue |
| Janssen Pharmaceuticals, INC | $577.89 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $442.86 | 2019-2023 | |
| Pfizer INC. | $331.74 | 2022-2025 | |
| Teleflex LLC | $299.71 | 2019-2025 | Manta, Turnpike |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $288.71 | 2021-2025 | Lifevest |
| Amgen INC. | $256.62 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $186.43 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $181.55 | 2020-2025 | Farxiga |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $180.10 | 2025 | |
| Abiomed | $166.81 | 2023-2025 | Impella |
| Merck Sharp & Dohme LLC | $156.08 | 2024-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $143.93 | 2021-2025 | Camzyos |
| Recor Medical INC | $124.15 | 2025 | Paradise Ultrasound Renal Denervation System |
| Arrow International, INC. | $121.09 | 2022 | |
| Kestra Medical Technology Services, INC. | $104.25 | 2025 | Assure Wcd |
| Inspire Medical Systems, INC. | $92.76 | 2025 | Inspire |
| Bridgebio Pharma, INC. | $65.35 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $56.15 | 2021-2025 | Nexletol |
| Chiesi USA, INC. | $55.28 | 2019-2024 | Kengreal |
| Alnylam Pharmaceuticals INC. | $40.63 | 2024-2025 | Amvuttra |
| Scpharmaceuticals INC. | $35.81 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $35.49 | 2023-2024 | Opsumit, Uptravi |
| Cardiovascular Systems INC. | $27.90 | 2022 | |
| Cardinal Health 200 LLC | $17.79 | 2019 | |
| Shockwave Medical, INC | $16.50 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.64 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $13.62 | 2019 | |
| Osprey Medical INC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Elmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.